185 related articles for article (PubMed ID: 29925769)
21. Novel pyrrolopyrimidines as Mps1/TTK kinase inhibitors for breast cancer.
Sugimoto Y; Sawant DB; Fisk HA; Mao L; Li C; Chettiar S; Li PK; Darby MV; Brueggemeier RW
Bioorg Med Chem; 2017 Apr; 25(7):2156-2166. PubMed ID: 28259529
[TBL] [Abstract][Full Text] [Related]
22. Rapid Discovery of Pyrido[3,4-d]pyrimidine Inhibitors of Monopolar Spindle Kinase 1 (MPS1) Using a Structure-Based Hybridization Approach.
Innocenti P; Woodward HL; Solanki S; Naud S; Westwood IM; Cronin N; Hayes A; Roberts J; Henley AT; Baker R; Faisal A; Mak GW; Box G; Valenti M; De Haven Brandon A; O'Fee L; Saville H; Schmitt J; Matijssen B; Burke R; van Montfort RL; Raynaud FI; Eccles SA; Linardopoulos S; Blagg J; Hoelder S
J Med Chem; 2016 Apr; 59(8):3671-88. PubMed ID: 27055065
[TBL] [Abstract][Full Text] [Related]
23. Novel Mps1 Kinase Inhibitors with Potent Antitumor Activity.
Wengner AM; Siemeister G; Koppitz M; Schulze V; Kosemund D; Klar U; Stoeckigt D; Neuhaus R; Lienau P; Bader B; Prechtl S; Raschke M; Frisk AL; von Ahsen O; Michels M; Kreft B; von Nussbaum F; Brands M; Mumberg D; Ziegelbauer K
Mol Cancer Ther; 2016 Apr; 15(4):583-92. PubMed ID: 26832791
[TBL] [Abstract][Full Text] [Related]
24. Functional characterization of CFI-402257, a potent and selective Mps1/TTK kinase inhibitor, for the treatment of cancer.
Mason JM; Wei X; Fletcher GC; Kiarash R; Brokx R; Hodgson R; Beletskaya I; Bray MR; Mak TW
Proc Natl Acad Sci U S A; 2017 Mar; 114(12):3127-3132. PubMed ID: 28270606
[TBL] [Abstract][Full Text] [Related]
25. Indazole-based potent and cell-active Mps1 kinase inhibitors: rational design from pan-kinase inhibitor anthrapyrazolone (SP600125).
Kusakabe K; Ide N; Daigo Y; Tachibana Y; Itoh T; Yamamoto T; Hashizume H; Hato Y; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Yasuo K; Maeda M; Higaki M; Ueda K; Yoshizawa H; Baba Y; Shiota T; Murai H; Nakamura Y
J Med Chem; 2013 Jun; 56(11):4343-56. PubMed ID: 23634759
[TBL] [Abstract][Full Text] [Related]
26. Preferential killing of p53-deficient cancer cells by reversine.
Jemaà M; Galluzzi L; Kepp O; Boilève A; Lissa D; Senovilla L; Harper F; Pierron G; Berardinelli F; Antoccia A; Castedo M; Vitale I; Kroemer G
Cell Cycle; 2012 Jun; 11(11):2149-58. PubMed ID: 22592527
[TBL] [Abstract][Full Text] [Related]
27. Mps1 inhibitors synergise with low doses of taxanes in promoting tumour cell death by enhancement of errors in cell division.
Maia ARR; Linder S; Song JY; Vaarting C; Boon U; Pritchard CEJ; Velds A; Huijbers IJ; van Tellingen O; Jonkers J; Medema RH
Br J Cancer; 2018 Jun; 118(12):1586-1595. PubMed ID: 29736010
[TBL] [Abstract][Full Text] [Related]
28. Hijacking monopolar spindle 1 (MPS1) for various cancer types by small molecular inhibitors: Deep insights from a decade of research and patents.
Liang C; Zhou Y; Xin L; Kang K; Tian L; Zhang D; Li H; Zhao Q; Gao H; Shi Z
Eur J Med Chem; 2024 Jul; 273():116504. PubMed ID: 38795520
[TBL] [Abstract][Full Text] [Related]
29. Discovery of 4-(4-aminopyrazolo[1,5-a][1,3,5]triazin-8-yl)benzamides as novel, highly potent and selective, orally bioavailable inhibitors of Tyrosine Threonine Kinase, TTK.
Laufer R; Li SW; Liu Y; Ng G; Lang Y; Feher M; Brokx R; Beletskaya I; Hodgson R; Mao G; Plotnikova O; Awrey DE; Mason JM; Wei X; Lin DC; Che Y; Kiarash R; Madeira B; Fletcher GC; Mak TW; Bray MR; Pauls HW
Bioorg Med Chem Lett; 2016 Aug; 26(15):3562-6. PubMed ID: 27335255
[TBL] [Abstract][Full Text] [Related]
30. Biophysical and X-ray crystallographic analysis of Mps1 kinase inhibitor complexes.
Chu ML; Lang Z; Chavas LM; Neres J; Fedorova OS; Tabernero L; Cherry M; Williams DH; Douglas KT; Eyers PA
Biochemistry; 2010 Mar; 49(8):1689-701. PubMed ID: 20099905
[TBL] [Abstract][Full Text] [Related]
31. A crystal structure of the human protein kinase Mps1 reveals an ordered conformation of the activation loop.
Roorda JC; Joosten RP; Perrakis A; Hiruma Y
Proteins; 2019 Apr; 87(4):348-352. PubMed ID: 30582207
[TBL] [Abstract][Full Text] [Related]
32. Development of the First Covalent Monopolar Spindle Kinase 1 (MPS1/TTK) Inhibitor.
M Serafim RA; da Silva Santiago A; Schwalm MP; Hu Z; Dos Reis CV; Takarada JE; Mezzomo P; Massirer KB; Kudolo M; Gerstenecker S; Chaikuad A; Zender L; Knapp S; Laufer S; Couñago RM; Gehringer M
J Med Chem; 2022 Feb; 65(4):3173-3192. PubMed ID: 35167750
[TBL] [Abstract][Full Text] [Related]
33. P-loop conformation governed crizotinib resistance in G2032R-mutated ROS1 tyrosine kinase: clues from free energy landscape.
Sun H; Li Y; Tian S; Wang J; Hou T
PLoS Comput Biol; 2014 Jul; 10(7):e1003729. PubMed ID: 25033171
[TBL] [Abstract][Full Text] [Related]
34. Whole-genome duplication increases tumor cell sensitivity to MPS1 inhibition.
Jemaà M; Manic G; Lledo G; Lissa D; Reynes C; Morin N; Chibon F; Sistigu A; Castedo M; Vitale I; Kroemer G; Abrieu A
Oncotarget; 2016 Jan; 7(1):885-901. PubMed ID: 26637805
[TBL] [Abstract][Full Text] [Related]
35. Structure-based design of orally bioavailable 1H-pyrrolo[3,2-c]pyridine inhibitors of mitotic kinase monopolar spindle 1 (MPS1).
Naud S; Westwood IM; Faisal A; Sheldrake P; Bavetsias V; Atrash B; Cheung KM; Liu M; Hayes A; Schmitt J; Wood A; Choi V; Boxall K; Mak G; Gurden M; Valenti M; de Haven Brandon A; Henley A; Baker R; McAndrew C; Matijssen B; Burke R; Hoelder S; Eccles SA; Raynaud FI; Linardopoulos S; van Montfort RL; Blagg J
J Med Chem; 2013 Dec; 56(24):10045-65. PubMed ID: 24256217
[TBL] [Abstract][Full Text] [Related]
36. Discovery of imidazo[1,2-b]pyridazine derivatives: selective and orally available Mps1 (TTK) kinase inhibitors exhibiting remarkable antiproliferative activity.
Kusakabe K; Ide N; Daigo Y; Itoh T; Yamamoto T; Hashizume H; Nozu K; Yoshida H; Tadano G; Tagashira S; Higashino K; Okano Y; Sato Y; Inoue M; Iguchi M; Kanazawa T; Ishioka Y; Dohi K; Kido Y; Sakamoto S; Ando S; Maeda M; Higaki M; Baba Y; Nakamura Y
J Med Chem; 2015 Feb; 58(4):1760-75. PubMed ID: 25625617
[TBL] [Abstract][Full Text] [Related]
37. Lead optimization of purine based orally bioavailable Mps1 (TTK) inhibitors.
Vijay Kumar D; Hoarau C; Bursavich M; Slattum P; Gerrish D; Yager K; Saunders M; Shenderovich M; Roth BL; McKinnon R; Chan A; Cimbora DM; Bradford C; Reeves L; Patton S; Papac DI; Williams BL; Carlson RO
Bioorg Med Chem Lett; 2012 Jul; 22(13):4377-85. PubMed ID: 22632936
[TBL] [Abstract][Full Text] [Related]
38. Leader of the SAC: molecular mechanisms of Mps1/TTK regulation in mitosis.
Pachis ST; Kops GJPL
Open Biol; 2018 Aug; 8(8):. PubMed ID: 30111590
[TBL] [Abstract][Full Text] [Related]
39. Disruption of the anaphase-promoting complex confers resistance to TTK inhibitors in triple-negative breast cancer.
Thu KL; Silvester J; Elliott MJ; Ba-Alawi W; Duncan MH; Elia AC; Mer AS; Smirnov P; Safikhani Z; Haibe-Kains B; Mak TW; Cescon DW
Proc Natl Acad Sci U S A; 2018 Feb; 115(7):E1570-E1577. PubMed ID: 29378962
[TBL] [Abstract][Full Text] [Related]
40. Scaffold-focused virtual screening: prospective application to the discovery of TTK inhibitors.
Langdon SR; Westwood IM; van Montfort RL; Brown N; Blagg J
J Chem Inf Model; 2013 May; 53(5):1100-12. PubMed ID: 23672464
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
